'Ifx' presentation slideshows

Management of CD Biological Agents

APDW IBD-Working Party Crohns Disease Consensus Statements 2011. Management of CD Biological Agents. Associate Professor Rupert WL Leong Director of Endoscopy, Concord Hospital University of New South Wales, Sydney Australia. Quality of Evidence. Major publication(s)

1.28k views • 112 slides

Literature Review

449 views • 37 slides

Literature Review

448 views • 37 slides

Measurements and Simulations of Surface Radiation Damage Effects on IFX and HPK Test Structures

Measurements and Simulations of Surface Radiation Damage Effects on IFX and HPK Test Structures. F. Moscatelli a,b , A. Morozzi b,c , D. Passeri b,c , S . Mattiazzo d , G.-F. Dalla Betta e,f , V. Hinger g and G. M. Bilei b. a CNR-IOM of Perugia, via Pascoli 1, 06123, Perugia, Italy

328 views • 32 slides

Robert N. Baldassano, MD Colman Professor of Pediatrics

What do we do when the patient loses their response to an anti-TNF: Minor tweaks or major treatment changes?. Robert N. Baldassano, MD Colman Professor of Pediatrics University of Pennsylvania, Perelman School of Medicine Director, Center for Pediatric IBD

409 views • 29 slides

<IFX_Forum_Annual_Meeting>

<IFX_Forum_Annual_Meeting>. </World_As_We_Know_It> April 23, 2003. A very productive year. Release of version 1.4 Progress on 1.5 and a next generation of IFX that can leverage the infrastructure work being done elsewhere Adoption, though quiet, is in evidence. A very Productive Year.

265 views • 20 slides

DAS 28 in Belgium

DAS 28 in Belgium. Prof. F. De Keyser. Introduction of DAS 28 in Belgian rheumatology. Background RTX reimbursement since June 2007 K55 nomenclature since Feb. 2009 1) Why the DAS 28 ? 2) Which cut-off should alert for a change in therapy? 3) Rituximab and DAS 28. 1) Why DAS 28 ?.

316 views • 10 slides